LeonaBio, Inc.
NCM: LONALive Quote
📈 ZcoreAI Score
Our AI model analyzes LeonaBio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LONA Z-Score →About LeonaBio, Inc.
Healthcare
Biotechnology
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
📊 Fundamental Analysis
LeonaBio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -290.8%, which indicates that capital utilization is currently under pressure.
At a current price of $9.69, LONA currently sits at the 62nd percentile of its 52-week range (Range: $2.20 - $14.21).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$91.02M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
2.23
52W High
$14.21
52W Low
$2.20
Avg Volume
68K
Day High
Day Low